Twenty human proteins encode Phox/Bem1p (PB1) domains, which are involved in forming protein heterodimers. MEKK2, MEKK3, and MEK5 are 3 serine-threonine protein kinases that have PB1 domains. MEKK2, MEKK3, and MEK5 are the MAP3Ks and the MAP2K in the ERK5 mitogen-activated protein kinase (MAPK) signaling module. ERK5 is a critical MAPK for both development of the vasculature and vascular homeostasis in the adult, but no other MAPK has been shown to be critical in vascular maintenance in the adult animal. MEKK2 and MEKK3 are the only MAP3Ks shown to physically interact with and activate the MEK5-ERK5 signaling module. Interaction of MEKK2 or MEKK3 with MEK5 is mediated by heterodimerization of the MEKK2 (or MEKK3) PB1 and MEK5 PB1 domains. The authors have developed a homogeneous, time-resolved fluorescence resonance energy transfer (TR-FRET) assay to monitor PB1-PB1 domain heterodimerization. The assay uses a europium-chelate conjugated GST-MEK5 PB1 domain chimera, biotinylated MEKK2 PB1 domain, and streptavidin-Cy5. Interaction of the MEKK2 and MEK5 PB1 domains gives a robust FRET signal (Z′ factor = 0.93), which is completely abrogated by mutation of 2 acidic residues ( 64 D 65 E→AA) within the MEK5 PB1 domain that causes loss of stable PB1-PB1 domain interaction. This assay can be used to study the specificity of PB1-PB1 domain interactions and to screen for molecules that can regulate MEKK2/MEKK3-MEK5 interactions. Disruption of PB1 domain interactions represents a novel approach for selectively regulating the ERK5 signaling pathway independent of kinase active site-directed adenosine triphosphate competitive inhibitors. (Journal of Biomolecular Screening 2008:396-405) 
INTRODUCTION
E RK5, ALSO KNOWN AS BMK1, IS ACTIVATED by a variety of growth factors and stress stimuli. 1 ERK5 appears to be expressed in most cells of adult mice and humans. 2 To date, defined substrates for ERK5 include connexin 43, 3 RSK, 4 SGK, 5 and the transcription factors MEF2A, -C, and -D; 6 SAP1A; 7 and PPARγ1. 8 A primary function of ERK5 appears to be protecting many cell types from stress-induced apoptosis. 9 In adult mice, conditional deletion of ERK5 resulted in loss of vascular integrity and endothelial cell survival and collapse of the vasculature. 10 ERK5 has also been shown to be essential for tumor-associated angiogenesis, 11 indicating that the MEKK2/3-MEK5-ERK5 pathway is a potentially important cancer therapeutic target.
Among all kinases in the mitogen-activated protein kinase (MAPK) signaling network, MEK5, MEKK2, and MEKK3 are unique in that they encode PB1 domains. 12 PB1 domains are used to form heterodimers between proteins such as MEKK2 (or MEKK3) and MEK5, using a ubiquitin-like β grasp topology in a front-to-back orientation of the 2 PB1 domains. 13 Other proteins encoding PB1 domains include the atypical protein kinases C (PKCs), PKCι and PKCζ; the adapter proteins p62 and PAR6; and p67 phox and p40 phox proteins of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. 14, 15 Structural analyses of PB1 domains have demonstrated a significant conservation of front-end basic and rearend acidic residues that interact in a β grasp-like topology. 13 PB1 domains have been classified into A-, B-, or AB-type PB1 domains depending on their mechanism of interaction with other PB1 domains. A-type PB1 domains use their acidic cluster, B-type PB1 domains use their basic cluster, and AB-type PB1 domains use both the basic and acidic clusters to bind other PB1 domains. 14 Using this classification, MEKK2 and MEKK3 have B-type and MEK5 A-type PB1 domains. Thus, MEKK2 (or MEKK3) and MEK5 form A-B PB1 domain heterodimers.
We have previously shown that the interaction of the MEKK2 or MEKK3 PB1 domain with the PB1 domain of MEK5 is absolutely required for the formation and organization of the MEKK2/3-MEK5-ERK5 signaling complex. 12, 16, 17 Furthermore, stimulus-dependent activation of ERK5 requires a functional MEKK2 (or MEKK3)-MEK5 interaction dependent on PB1 domain heterodimerization. 12, 17 Herein, we characterize a robust time-resolved fluorescence resonance energy transfer (TR-FRET) assay, which is highly cost-efficient and has a broad dynamic range and reproducibility suitable for the study of PB1-PB1 domain interactions and screening of small molecules that regulate PB1 domain function.
MATERIALS AND METHODS

General reagents
LANCE Eu-W1024 anti-GST-Ab and Cy5-streptavidin were purchased from PerkinElmer (Waltham, MA) and Amersham Biosciences (Piscataway, NJ), respectively. Prestwick chemical library was obtained from Prestwick Chemical (Illkirch, France). The 33,600-compound combinatorial chemical library was a diverse subset of a 350,000-member combinatorial compound library donated as a gift to BRITE by Biogen Idec, Inc. (Cambridge, MA). The 96-well half-area and 384-well black plates were from Corning (Corning, NY).
DNA constructs
GST-MEK5 (a.a. 18-131) fusion (wild-type and mutant [ 64 D 65 E-AA]) was constructed in pGEX 5X-1 (Amersham) using the cDNA fragments amplified by PCR. The indicated specific residues replaced by alanine (A) were prepared using PCR-based mutagenesis. For the Avi-tag-MEKK2 PB1 domain, a cDNA encoding hexa-histidine tagged MEKK2 PB1 domain (a.a. 35-127) was generated by PCR and cloned into the Avi-tag (pAN4 vector) vector (Avidity, Aurora, CO).
Preparation of recombinant proteins
GST-MEK5 fusion protein in growing Escherichia coli strain (XL-1 Blue) treated with 250 μM isopropyl-β-D-thiogalactopyranoside (IPTG) was extracted by 1% Triton in phosphate-buffered saline (PBS) with sonication. Protein was purified using glutathione-Sepharose beads (Amersham) and resuspended in 100 mM HEPES buffer (pH 8.0) for europium (Eu)-chelate labeling. Avitag 6xHis-MEKK2 PB1 domain in pAN4 vector (Avidity) was introduced into AVB101 E. coli strain containing a chloramphenicolresistant plasmid and IPTG-inducible birA gene to overexpress biotin ligase. Biotin ligase activates biotin to form biotinyl 5′ adenylate in the presence of adenosine triphosphate (ATP) and transfers the biotin to the lysine residue in the biotin Avi-tag sequence. Transformed E. coli in logarithmic growth were incubated with 250 μM IPTG and 50 μM biotin for 2.5 h and harvested. The recombinant biotinylated protein was purified by Ni-His interaction and dialyzed against 100 mM NaCl and 50 mM Tris (pH 8.0). Quantitative anti-His Ab blot using streptavidinagarose beads confirmed that biotinylation efficiency of the Avitag-His-tag MEKK2 PB1 protein was more than 95%.
Labeling of GST-MEK5 with Eu-chelate
Purified GST-MEK5 fusion protein was labeled with iodoacetamido (IAA)-activated Eu-W1284 chelate (PerkinElmer). In brief, 50 μM purified GST-MEK5 PB1 domain in 2.5 mM EDTA, 100 mM HEPES buffer (pH 8.0), was incubated with 0.4 mM (8 times molar excess over protein) IAA-activated Eu-chelate in the presence of 0.5 mM Tris(2-carboxyethyl)phosphine hydrocloride (TCEP) (10 times higher than protein concentration) overnight at 4 °C. Purification and buffer exchange of the labeled protein was conducted by gel filtration using Sephadex G-25 beads. Purified protein was eluted in 100 mM NaCl, 0.02% sodium azide (NaN 3 ), and 50 mM Tris (pH 8.0). Concentration of labeled protein was determined by the Bradford method. Covalent coupling of Euchelate was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation under UV light. The efficiency of GST-MEK5 labeling by IAA-activated Mero-53 18 was estimated by using the dye absorbance at 590 nm and the protein absorbance at 280 nm (labeling efficiency = molar amount of dye/molar amount of protein). Absorbance spectra of labeled proteins were obtained in a Hewlett Packard 8453 UV-Vis spectrophotometer. An absorbance ratio of A 280 /A 590 = 0.082 of free Mero-53 dye in H 2 O was used to correct for the contribution of dye absorbance at 280 nm to the estimation of protein concentration.
TR-FRET assay
The assay was performed at 23 °C in either 96-or 384-well microplates. The indicated amount of biotinylated MEKK2 PB1 domain and Eu-labeled or unlabeled GST-MEK5 (a.a. 18-131) and 10 nM Cy5-streptavidin were mixed in an assay buffer (150 mM NaCl, 10 mM Tris [pH 8.0], 0.1% bovine serum albumin [BSA], and 0.02% NaN 3 ). In assays in which the GST-MEK5 fusion protein was not directly europium labeled, 10 nM Eu-anti-GST Ab was added into a reaction. The final assay volume was 50 μL. To complete the binding reaction, the plates were incubated for the indicated time period. TR-FRET signal was measured using a PHERAstar plate reader (BMG Labtech, Offenburg, Germany). The Eu-chelate donor was excited at 337 nm. Emission of Eu and Cy5 was measured with 620-and 665-nm emission filters, respectively. Cy5 emission, divided by the Eu emission and multiplied by 10,000, was used as the TR-FRET signal value. After an 80-μs postexcitation delay, a 400-μs integration time was used for the signal detection, with 400 flashes per well. Z′ factor was calculated according to the following equation: Z′ = 1 -3 × (σ p + σ n )/|μ p -μ n |, where σ p and σ n are the standard deviations of the positive (with biotin-MEKK2) and negative (without biotin-MEKK2) controls, respectively, and μ p and μ n are average values for the positive and negative controls, respectively.
For the high-throughput screen of a chemical library, 0.5 μL of the 1-mM compound in 100% DMSO was added to dry 384-well plates using a Biomek NX (Beckman, Fullerton, CA), resulting in a final compound concentration of 10 μM for the primary screen. The Multidrop (Thermo, Waltham, MA) automated liquid dispenser device was used to deliver assay reagents to the wells. To the plates containing compound, 25 μL of assay buffer containing Eu-labeled GST-MEK5 and Cy5-streptavidin was added followed by a 20-min incubation. Subsequently, 25 μL of assay buffer containing biotin-MEKK2 was added, followed by at least a 10-min incubation before measuring the TR-FRET signal. Final assay concentrations were 1% DMSO, 1 nM Eu-labeled GST-MEK5, 10 nM Cy5-streptavidin, and 10 nM biotin-MEKK2. Maximum signal positive control wells contained only DMSO (no compound), whereas the minimum signal control wells were obtained by using assay buffer without biotin-MEKK2 in the second liquid addition. Addition of unlabeled MEK5 PB1 domain to the assay competitively inhibited the TR-FRET response, demonstrating that the signal is a function of PB1 domain dimerization. Percent inhibition of each compound is calculated by the following equation: 1 -(TR-FRET value -μ n )/(μ p -μ n ), multiplied by 100, where μ p and μ n are average values for the positive and negative controls, respectively. The definition of hit was a compound that displayed ≥50% inhibition in the primary screen.
IC 50 value was defined as the concentration of inhibitor that generated a 50% reduction in assay signal. Values and Hill slopes were calculated using either a 4-or 3-parameter doseresponse (variable slope) equation. For the IC 50 determinations, a serial dilution of compound was performed in 100% DMSO with a 2-fold dilution scheme resulting in 10 concentrations of compound starting at a high concentration of 20 μM compound in the final assay. These compound dilutions were spotted onto plates and the assay performed at 1% DMSO final concentration as described for the primary screen.
RESULTS
Design of MEKK2-MEK5 PB1 domain TR-FRET assay
We have previously demonstrated both in vitro and in vivo the interaction of the MEK5 PB1 domain (a.a. 18-131) and MEKK2 PB1 domain (a.a. 35-127) using multiple independent methods, including glutathione-S-transferase (GST) pull-down, coimmunoprecipitation, and FRET assays using CFP-and YFP-tagged versions of the MEKK2 and MEK5 PB1 domains. 12, 16, 17 To further define the properties and regulation of MEK5-MEKK2 PB1 domain interactions, a homogeneous TR-FRET assay was developed for measurement of PB1-PB1 domain heterodimerization using recombinant GST-MEK5 PB1 domain chimeric protein and MEKK2 PB1 domain having an Avi-tag sequence for biotinylation ( Fig. 1A) . Eu-tagged anti-GST antibody and Cy5-streptavidin were used as FRET pairs in the assay. The original assay had a 6fold signal-to-background ratio and a high Z′ factor >0.75, and it was used to assay the ability of wild-type and mutant forms of the MEK5 and MEKK2 proteins to disrupt PB1-PB1 domain interactions. 17 The cost of the Eu-tagged anti-GST antibody proved prohibitive for performing high-throughput screening (HTS) of large chemical collections. Therefore, we set out to develop a more robust assay that would be highly cost-effective and allow both structure-function studies of PB1-PB1 domain interactions and high-throughput screens to identify molecules that regulate the heterodimerization of specific PB1 domains.
As a feasible alternative to the use of Eu-tagged antibodies, we developed a simple and highly reproducible method to directly label the glutathione-S-transferase (GST) moiety of the GST-MEK5 PB1 domain chimera with Eu-chelate ( Fig. 1B) . GST has 4 cysteines as potential labeling sites for sulfhydryl modification by IAA-activated Eu-chelate, whereas there are no cysteines in the MEK5 PB1 domain (a.a. 18-131). To optimize conditions for labeling sulfhydryl groups in GST, the fluorescent dye IAA-Mero-53 18 was used to allow fluorescence monitoring of the reaction. The purified recombinant GST-MEK5 PB1 domain was poorly labeled with IAA-activated Mero-53. Simple addition of TCEP, a sulfhydryl reductant that does not interfere with -SH derivatization, 19 made the GST labeling highly efficient, increasing derivatization 3-fold (Fig. 2) , and the high labeling efficiency in the presence of TCEP was reproducible between different preparations of the GST-MEK5 PB1 domain. Figure 3 shows the comparison of the 2 TR-FRET assays. The assay using Eu-tagged anti-GST antibody and Cy5-streptavidin ( Fig. 1A) was optimal at the 100-nM biotin-MEKK2 and 10-nM GST-MEK5 proteins, so these conditions were compared with similar concentrations of the Eu-chelate-conjugated MEK5 PB1 domain and biotin-labeled MEKK2 PB1 domain ( Fig. 3) . Direct Eu-chelate conjugation of the GST-MEK5 PB1 domain increased the FRET signal greater than 16-fold compared with use of the Eutagged anti-GST antibody. We have demonstrated that mutation in the acidic cluster of the MEK5 PB1 domain ( 64 D 65 E→AA) completely abrogates stable heterodimerization of the MEK5 and MEKK2 PB1 domains. 12, 16, 17 This mutation ( 64 D 65 E-AA) in the MEK5 PB1 domain completely inhibited the TR-FRET signal in both assay conditions, demonstrating the stringent requirement for PB1-PB1 domain heterodimerization for obtaining the FRET signal. The Eu-chelate-labeled GST-MEK5 PB1 domain makes the assay simple and straightforward for the study of PB1 domain interactions.
Optimization of the PB1 domain heterodimerization TR-FRET assay
A matrix analysis was conducted with serial dilutions of the Eu-GST-MEK5 PB1 domain (1-100 nM) and biotin-MEKK2 PB1 domain (1-1000 nM) to optimize protein ratios in the assay (Fig.  4A) . Based on relative TR-FRET values observed with or without the biotin-MEKK2 PB1 domain, a concentration of the 10-nM biotin-MEKK2 PB1 domain and 1-nM Eu-GST-MEK5 PB1 domain was determined to provide an excellent signal-to-background ratio (approximately 28-fold) while conserving protein reagents. Accordingly, the subsequent validation assay was tested at these protein concentrations. These concentrations are approximately one tenth the protein levels required using the Eu-anti-GST antibody. To verify the minimum assay signal, we evaluated the TR-FRET signal in the presence of the unlabeled MEK5 PB1 domain protein (Fig. 4B) . With the unlabeled protein, TR-FRET signal was dose-dependently decreased to the TR-FERT value comparable to the value without biotin-MEKK2 probe, whereas unlabeled 64 D 65 E-AA mutant showed no inhibition even at high concentrations. In the following study, we thus used TR-FRET signal without biotin-MEKK2 protein as a minimum signal control.
HTS assay design and characterization
The TR-FRET signal was not changed when the addition order of Eu-GST-MEK5 PB1 domain, biotin-MEKK2 PB1 domain, and Cy5-streptavidin was varied (data not shown). Structures derived from nuclear magnetic resonance (NMR) and X-ray crystallography data indicate that the MEK5 acidic cluster has a defined binding pocket that potentially could bind small molecules. 13, 20 For screens of small-molecule inhibitors of PB1-PB1 domain interactions, it may be beneficial to expose the MEK5 PB1 domain to small molecules prior to the addition of the MEKK2 PB1 domain. 21 For this reason, a 25-μL mixture of 2 nM Eu-GST-MEK5 PB1 domain and 20 nM Cy5-streptavidin was added to each well followed by the addition 25 μL of 20 nM biotin-MEKK2 PB1 domain or buffer (for minimum signal control), resulting in 1 nM Eu-MEK5 PB1 domain, 10 nM Cy5-streptavidin, and 10 nM biotin-MEKK2 PB1 domain in a final assay volume of 50 μL. For compound screening, plates were prespotted with 0.5 μL of library compound in each well, providing an assay that was a simple 2-step mix-andmeasure procedure.
The binding reaction was completed within 10 min after addition of the biotin-MEKK2 PB1 domain, and the signal was stable for 1.5 h, then decreased slowly; a total decrease of approximately 20% was observed at 6 h (Fig. 5A) . The calculated coefficient of variation (CV) and Z′ factor were <5% and >0.88, respectively, at each time point. In addition, we tested the effect of EDTA and MgCl 2 on the assay (Fig. 5B, C) . There was no obvious effect of these additives on the FRET signal at concentrations up to 2 mM EDTA and 1 mM MgCl 2 . Compounds in screening libraries are typically dissolved in 100% DMSO. Therefore, the effect of DMSO on the assay signal was tested (Fig. 5D) . There was no significant effect up to 1% DMSO, whereas 2% and 4% DMSO resulted in a modest increase in signal. Thus, the assay signal is relatively stable over time, tolerant of DMSO concentrations that occur in small-molecule screens and resistant to low concentrations of the most commonly used metal ion chelator.
Assay validation
The variability of the assay described above was characterized in a 384-well plate format. The HTS version of the TR-FRET assay employed workstation-level automated liquid handling systems, including Biomek NX for compound delivery and the Multidrop for reagent delivery to the plate. Entire 384-well plates prespotted with 0.5 μL DMSO were used to measure the maximum (Max), midpoint (Mid), and minimum (Min) TR-FRET signals. The CVs for Max and Min were 2.2% and 4.3%, respectively. The more than 37-fold signal-to-background ratio and low CVs provided a large assay window, resulting in a Z′ factor of 0.93. In addition to analyzing Max and Min signal variability, the scattering of the plots was analyzed with a diluted biotin-MEKK2 PB1 domain, which gave an approximate half-maximal TR-FRET signal (Fig. 6A) . The calculated CV of this Mid signal was 6.3%, with these values well separated from Max and Min TR-FRET signals (Fig. 6B) . Therefore, a 50% inhibition value was chosen for the active cutoff. Thus, the assay is highly robust with good variability amenable for HTS. 
Prestwick collection library screening
As an initial test screen, the TR-FRET assay was interrogated using the Prestwick chemical library, a collection of 1120 compounds, of which 90% are drugs approved by the Food and Drug Administration (FDA). This set of compounds provided chemical and pharmacological diversity to test the performance of the assay in the presence of diverse compounds. Screening of this library resulted in 3 compounds that were found to inhibit the PB1-PB1 domain heterodimerization assay (Fig. 7) . One hit completely inhibited the FRET signal. This compound was biotin and therefore would be expected to inhibit the binding of streptavidin-Cy5 to the biotin-MEKK2 PB1 domain. The other 2 compounds yielded 50% to 60% inhibition of the FRET signal; these 2 compounds are detergent-like antibiotics and were not followed up.
Screening of a combinatorial chemistry library
A library of 33,600 compounds was screened using the above validated assay at a compound concentration of 10 μM. The 350,000-member combinatorial chemical library was originally created in 96-well plates where each plate contained structurally related compounds. A diverse subset of these 96-well plates was condensed into 384-well plates such that there were 4 unrelated chemical libraries per 384-well plate. This created a checkerboard pattern of structurally related compounds on the 384-well plate, allowing a limited structure-activity relationship to be discerned from the screen. Because the reagents were added via Multidrop liquid addition which progresses by rows and not quadrants, any checkerboard pattern of hits would be unlikely to be caused by screening artifacts. Of the 33,600 compounds, 180 were shown to inhibit the TR-FRET signal ≥50%, for an active rate of 0.5% (Fig.  8A) . These 180 compounds were retested in IC 50 value determination assays using the same TR-FRET PB1 domain interaction assay. From the set of 180 actives, 140 compounds were confirmed at the ≤20-μM IC 50 value for a repeat rate of 78%. The IC 50 curves were manually examined, and the Hill coefficient values were used to prioritize actives (Fig. 8B) . In this TR-FRET assay, the MEK5 competition experiment shown in Figure 4B demonstrates a Hill coefficient of 1.013, which is almost identical to the ideal value of 1.0 for a competitive inhibitor. 22, 23 Therefore, the Hill coefficient (0.7-1.2) was used to prioritize compounds. These criteria resulted in prioritizing 20 compounds for secondary assays. These compounds had IC 50 potencies ranging from 0.8 to 20 μM. Of these 20 compounds, 7 related compounds were shown to partially quench the Eu signal, and therefore they were discarded as false positives. The remaining 13 compounds are currently being tested for purity and activity in a secondary PB1 domain interaction assay format that is independent of the TR-FRET assay.
DISCUSSION
Our goal in establishing an easy and straightforward assay for measuring PB1-PB1 domain interactions was 2-fold: first, allow the study of PB1 domain heterodimerization in vitro and, second, optimize a homogeneous assay for identifying smallmolecule regulators of PB1-PB1 domain interactions. The homogeneous TR-FRET assay we have characterized has a high Z′ factor and combines the benefits of both FRET and time-resolved fluorescence. Mutation of 2 residues in the MEK5 PB1 domain, 64 D 65 E-AA, which we have previously demonstrated disrupts PB1 domain interactions measured by the GST pull-down assay or CFP/YFP FRET-based assays in cells, 12, 16, 17 completely abrogated the TR-FRET signal in the PB1 domain heterodimerization assay. This result validates the TR-FRET assay as a highly sensitive measurement of in vitro PB1-PB1 domain interactions.
The use of direct Eu labeling of the GST-MEK5 PB1 domain provided a simple assay configuration that markedly lowers the assay cost per well. In the 384-well format, the direct Eu-labeled GST-MEK PB1 domain resulted in a reagent cost of approximately 1 to 2 cents per well. The use of commercially available Eu-tagged antibodies increased the cost of the assay more than 50fold. Our derivatization of the GST-MEK5 PB1 domain protein took advantage of the fact that the MEK5 PB1 domain does not encode a cysteine residue. Even in the event of protein domains harboring cysteines, it is likely that the IAA-Eu-chelate will be effective in labeling proteins that will retain activity in TR-FRET assays. 24 The addition of the reducing agent, TCEP, in the labeling reaction increased the coupling efficiency of Eu-chelate to cysteine in GST approximately 3-fold. We are now testing maltose-binding proteins with engineered cysteines for direct labeling by lanthanide chelates and fluorescence acceptor reagents with the goal of multiplexing TR-FRET assays.
Biologically, our focus on the MEKK2 (and MEKK3)-MEK5 PB1 domain interaction is related to the unique and stringent PB1 domain heterodimerization mechanism required for activation of the MEKK2/3-MEK5-ERK5 pathway. 12, 16, 17 The MEKK2/3-MEK5-ERK5 signaling complex organized by PB1 domain interaction appears critical for the regulation of vascularization and provides a potential new therapeutic target to inhibit angiogenesis in different human diseases. In particular, tumor vascularization may be extremely susceptible to disruption by small-molecule inhibitors of MEKK2/3-MEK5 PB1 domain interactions. The MEKK2/3-MEK5-ERK5 pathway is potentially a very important anticancer target that is required for tumor angiogenesis, as demonstrated in a conditional ERK5 knockout mouse, 11 and the role of ERK5 activation in supporting proliferation and survival by signaling downstream of activated Ras and overexpressed ErbB1 in prostate, breast, and leukemic tumor cells. 25 In addition to MEKK2, MEKK3, and MEK5, the adapter proteins p62/Zip and Par6, as well as the atypical PKCs (PKCι and PKCζ), also encode PB1 domains. PAR6 and the atypical PKCs form heterodimers in polarity complexes. 26 Associated with the aPKC-PAR6 complex is PAR3. Suzuki and Ohno 27 have termed this complex the aPKC complex because the aPKCs, PAR6, and PAR3 most often work as a functional unit. The PAR-aPKC system functions to localize and regulate the function of at least 30 additional proteins for the control of cell polarity. Among the cell polarity functions controlled by the PAR-aPKC system in mammalian cells are apical-basal polarity of epithelial cells, directed cell migration, axon determination, and epithelial-tomesenchymal transition (EMT). The adapter protein p62/Zip interacts with both the aPKCs and MEK5, 14, 15 suggesting that there may be a networking function for PB1 domains for regulating the integration of different signaling systems. Clearly, PB1 domain-encoded proteins have critical functions in the control of processes that, when dysregulated, are associated with human diseases. The TR-FRET assay we have developed is easily multiplexed to study structural determinants involved in controlling different PB1-PB1 domain interactions, to define specificity of PB1 domain interactions, and to discover small molecules and peptides that can regulate PB1-PB1 domain interactions. [1] [2] [3] [4] . Wells in columns 1, 2, 23, and 24 were spotted with DMSO. A 25-μL mixture of Eu-chelate-GST-MEK5 protein and Cy5-streptavidin was added to each well. After a 20-min incubation at room temperature, 25 μL of biotin-MEKK2 PB1 domain (3-24 in column) or buffer (1 and 2 in column) was added to each well. The reaction was incubated at room temperature for 10 min, and the TR-FRET signals were captured. On each plate, 32 wells in columns 1, 2, 23, and 24 are used for negative (no compounds or biotin-MEKK2 PB1 domain) and positive (no compounds) controls, respectively. In graphs, the x-axis shows column number (1-24) in a 384-well plate. Alphabet (A-P) in the legend indicates row number in a 384-well plate. A cutoff line (broken line) was set at 50% inhibition of a positive control in time-resolved fluorescence resonance energy transfer (TR-FRET) signal (5500). Coefficient of variation and Z′ factor for the assay are <4.4% and >0.90. 
